Literature DB >> 14745701

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.

Frederick G Hayden1, Robert Belshe, Catalina Villanueva, Riin Lanno, Claire Hughes, Ian Small, Regina Dutkowski, Penelope Ward, Jackie Carr.   

Abstract

We determined the efficacy of postexposure prophylaxis (PEP) and treatment of ill index cases with oseltamivir, in an attempt to prevent influenza transmission in households, in a study conducted in 277 households with 298 index cases (62% with laboratory-confirmed influenza) and 812 contacts aged > or =1 year. Contacts were randomized by household to receive treatment (5 days; n=402), if illness developed, or PEP for 10 days (n=410), and the number of households with at least 1 contact developing laboratory-confirmed influenza was measured. PEP provided a protective efficacy of 58.5% (95% confidence interval [CI], 15.6%-79.6%; P=.0114) for households against proven influenza and 68.0% (95% CI, 34.9%-84.2%; P=.0017) for individual contacts, compared with treatment of index cases alone. No oseltamivir-resistant variants were detected in treated index cases or contacts. PEP of household contacts of those with influenza reduces the secondary spread of influenza in families when the initial household case is treated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745701     DOI: 10.1086/381128

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  99 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Design and Evaluation of Prophylactic Interventions Using Infectious Disease Incidence Data from Close Contact Groups.

Authors:  Yang Yang; Ira M Longini; M Elizabeth Halloran
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2006-05       Impact factor: 1.864

3.  Stockpiling oseltamivir: Roche clarifies data for improved mortality with oseltamivir.

Authors:  James R Smith; Regina Dutkowski
Journal:  BMJ       Date:  2005-11-19

4.  Influenza pandemic preparedness in France: modelling the impact of interventions.

Authors:  Aoife Doyle; Isabelle Bonmarin; Daniel Lévy-Bruhl; Yann Le Strat; Jean-Claude Desenclos
Journal:  J Epidemiol Community Health       Date:  2006-05       Impact factor: 3.710

5.  Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.

Authors:  Beate Sander; Frederick G Hayden; Marlene Gyldmark; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 7.  The threat of avian influenza A (H5N1). Part III: Antiviral therapy.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-04-12       Impact factor: 3.402

8.  Estimating antiviral effectiveness against pandemic influenza using household data.

Authors:  Kathryn Glass; Niels G Becker
Journal:  J R Soc Interface       Date:  2008-12-05       Impact factor: 4.118

9.  The Jeremiah Metzger Lecture: avian influenza.

Authors:  John G Bartlett
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

Review 10.  Household transmission of 2009 pandemic influenza A (H1N1): a systematic review and meta-analysis.

Authors:  Lincoln L H Lau; Hiroshi Nishiura; Heath Kelly; Dennis K M Ip; Gabriel M Leung; Benjamin J Cowling
Journal:  Epidemiology       Date:  2012-07       Impact factor: 4.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.